SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

2/14/23 12:40:49 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $BRKR alert in real time by email

SC 13G/A 1 brkr13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Bruker Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 116794108 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 6,350,562 6. Shared Voting Power* 0 7. Sole Dispositive Power* 16,368,144 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 16,368,144 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 11.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: Bruker Corp Item 1(b) Address of Issuer's Principal Executive Offices: 40 MANNING RD, BILLERICA, MASSACHUSETTS 01821 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 116794108 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: February 14, 2023 Signature: /s/ Mary Ann Picciotto Name & Title: Mary Ann Picciotto, Vice President 12/31/2022

Get the next $BRKR alert in real time by email

Recent Analyst Ratings for

$BRKR

Date	Price Target	Rating	Analyst
10/15/2024	$75.00	Overweight	Barclays
9/30/2024		Outperform → Peer Perform	Wolfe Research
8/28/2024	$78.00	Overweight	Wells Fargo
6/3/2024	$85.00	Buy	Jefferies
2/14/2024	$60.00 → $90.00	Neutral → Overweight	JP Morgan
12/19/2023	$72.00	Equal Weight	Wells Fargo
12/13/2023	$80.00	Outperform	Wolfe Research
10/21/2022	$70.00	Buy	UBS

More analyst ratings

SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $BRKR

$BRKR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Bruker Corporation

Amendment: SEC Form SC 13G/A filed by Bruker Corporation

Amendment: SEC Form SC 13G/A filed by Bruker Corporation

$BRKR SEC Filings

Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Bruker Corporation

Bruker Corporation filed SEC Form 8-K: Leadership Update

$BRKR Market Insights

Live Market Insights

Bruker Posted Bond In Order To Suspend Injunction That Had Been Impacting Sales Of CosMx Spatial Molecular Imager Products By Its NanoString Business In Germany

Citigroup Maintains Buy on Bruker, Lowers Price Target to $80

Goldman Sachs Maintains Sell on Bruker, Lowers Price Target to $60

$BRKR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Barclays initiated coverage on Bruker with a new price target

Bruker downgraded by Wolfe Research

Wells Fargo initiated coverage on Bruker with a new price target

$BRKR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

$BRKR Press Releases

Fastest customizable press release news feed in the world

$BRKR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Bruker Announces Quarterly Dividend

Bruker Corporation to Present at Upcoming Investor Conferences

Dragonfly Energy and Bruker Partner to Accelerate Battery Technology Development

PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

Director Rosenthal Bob exercised 12,500 shares at a strike of $23.37 and sold $295,748 worth of shares (4,684 units at $63.14), increasing direct ownership by 34% to 30,963 units (SEC Form 4)

PRESIDENT CALID Srega Juergen was granted 16,936 shares, increasing direct ownership by 12% to 157,727 units (SEC Form 4)

$BRKR Leadership Updates

Live Leadership Updates

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Bruker Announces Agreement to Acquire Chemspeed

$BRKR Financials

Live finance-specific insights

Bruker Announces Quarterly Dividend

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Recent Analyst Ratings for
$BRKR

$BRKR
Large Ownership Changes

$BRKR
SEC Filings

$BRKR
Market Insights

$BRKR
Analyst Ratings

$BRKR
Insider Purchases

$BRKR
Press Releases

$BRKR
Insider Trading

$BRKR
Leadership Updates

$BRKR
Financials